How is lutetium-177 produced?
Lu is produced in a nuclear reactor through irradiation of a source material with neutrons. There are currently two ways to produce 177Lu, the carrier added way and the no carrier added way, see Fig. 1 [26]. The carrier added route uses stable lutetium as the material to irradiate with neutrons.
Where is lutetium-177 produced?
Lu-177 is one of a variety of medical radioisotopes that Shine intends to produce at its US medical isotope production facility in Janesville, Wisconsin, where a groundbreaking ceremony took place on 9 May. Commercial production of isotopes, including molybdenum-99, is scheduled to begin in 2021.
What types of radiation are produced in the radioactive decay of lutetium-177?
During these radioactive decay events, 177Lu emits β- particles with an E β(max) of 497 keV (78.6 %), 384 keV (9.1 %) and 176 keV (12.2 %) and low-energy gamma photons [Eγ = 113 keV (6.6 %), 208 keV (11 %)] [9, 10].
What particle is emitted when lutetium-177 is emitted?
Lu 177 emits high energy beta particles with an Eβ max = 497 keV (78.6 %), 384 keV (9.1 %) and 176 keV (12.2 %), and gamma photons Eγ = 208keV (11.1%), 113 keV (6.6%). There are also multiple low energy x-rays (65 keV or less), but emitted a small percent of time.
Who produces lutetium?
About lutetium-177 Lutetium-177 is a radioisotope produced by NRG.
Who manufactures Lutathera?
In the meantime, one Novartis radioligand therapy production site in Zaragoza, Spain, remains operational and is making Lutathera for Europe and Asia, although Novartis warns of possible delays in supply.
What is lutetium Lu 177 used for?
A radioactive drug used to treat adults with gastroenteropancreatic neuroendocrine tumors that are somatostatin receptor positive. It is also being studied in the treatment of other types of cancer.
When will lutetium be FDA approved?
On March 23, 2022, the FDA approved Pluvicto (active ingredient lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane-based …
Where is Lutathera manufactured?
The approval by the Italian Pharmaceutical Regulatory Authority will enable AAA to manufacture Lutathera® at its facility in Colleretto Giacosa, near Turin, Italy, making it the first industrial facility in the world approved to produce radio-labelled peptides for molecular nuclear therapy.
Where is Lutathera made?
Those expectations were not misplaced. In fact, demand for Lutathera is so high that AAA is planning to build a new 50,000-square-foot manufacturing plant in Indianapolis’ Purdue Research Park to make the drug and other radiotherapies, the Novartis unit said Tuesday.
Is lutetium-177 available in the US?
March 23, 2022 — The U.S. Food and Drug Administration (FDA) has approved lutetium-177 (Lu-177) prostate-specific membrane antigen radioligand therapy (Pluvicto, Novartis) for the treatment of patients with metastatic prostate cancer.
When will lutetium 177 be available?
In men with far-advanced, difficult-to-treat, metastatic prostate cancer, PSMA-targeted 177Lu has now been demonstrated to improve survival and health-related quality of life in a large phase III pivotal trial. FDA approval of 177Lu-PSMA-617 is anticipated in 2022.
Is lutetium 177 available in USA?
How is Lutathera made?
LUTATHERA is a radiopharmaceutical created by linking a radionuclide to a peptide that binds somatostatin receptors on the surface of GEP-NET tumor cells.
When will Lutetium-177 be available?
How is 177 Lu produced?
This is now on the initial step of its development. The 177 Lu production processes are based on irradiation of isotopically enriched 176 Lu or 176 Yb with reactor neutrons, followed by radiochemical processing of the irradiated targets.
Can 177Lu be produced large-scale for peptide receptor radionuclide therapy?
On the practical aspects of large-scale production of 177Lu for peptide receptor radionuclide therapy using direct neutron activation of 176Lu in a medium flux research reactor: The Indian experience. J Radioanal Nucl Chem. 2014;302:233–243. doi: 10.1007/s10967-014-3169-z.
How is the specific activity of 177Lu calculated?
Variation of the specific activity of 177Lu, theoretically calculated using k = 1.5, 2.0 and 2.5, with the duration of irradiation when the enriched (82 % in 176Lu) target is irradiated at a thermal neutron flux of 1.2 × 1014n.cm-2.s-1r The time of irradiation at which the maximum activity of 177Lu is achieved is expressed as [50]
What is the yield of 177Lu produced at FRM-II?
Dvorakova Z, Henkelmann R, Lin X, Turler A, Gerstenberg H. Production of 177Lu at the new research reactor FRM-II: irradiation yield of 176Lu(n, γ)177Lu. Appl Radiat Isot. 2008;66:147–151. doi: 10.1016/j.apradiso.2007.08.013.